Keros Therapeutics (KROS) Return on Sales (2019 - 2025)

Keros Therapeutics (KROS) has 7 years of Return on Sales data on file, last reported at 0.41% in Q4 2025.

• For the quarter ending Q4 2025, Return on Sales fell 131.0% year-over-year to 0.41%; the trailing twelve-month figure through Dec 2025 stood at 0.0% (down 1561.0% YoY), and the FY2025 full-year result was 0.0%, changed N/A from the prior year.
• Return on Sales for Q4 2025 stood at 0.41%, down from 0.01% in the prior quarter.
• Across five years, Return on Sales topped out at 0.91% in Q4 2024 and bottomed at 54.1% in Q3 2023.
• The 5-year median for Return on Sales is 0.06% (2022), against an average of 5.26%.
• The widest annual swing landed in 2023, when Return on Sales tumbled 5408 bps; it then jumped 5274 bps in 2024.
• A 5-year view of Return on Sales shows it stood at 0.0% in 2021, then slumped by 1400 bps to 0.06% in 2022, then plunged by 5486 bps to 3.25% in 2023, then soared by 128 bps to 0.91% in 2024, then plunged by 145 bps to 0.41% in 2025.
• The last three Return on Sales figures came in at 0.41% (Q4 2025), 0.01% (Q3 2025), and 0.02% (Q2 2025), per Business Quant data.

Peer Comparison